Wide morphological spectrums of renal neoplasms with TSC/mTOR, NF2, or monoallelic MUTYH germline mutation

Liu, Yang; Fan, Yue; Feng, Runlin; Zhou, Luting; Gu, Yijin; Dong, Lei; Yi, Hongmei; Yang, Xiaoqun; Wang, Chaofu

doi:10.1016/j.hpr.2023.300695

Cited by 1 publication

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these patients, there were two cases with non-BRCA GPVs, one case with synchronic prostate and renal cancer with a MUTYH GPV, and a case of synchronic BC and lung cancer with an ATM GPV. It has been reported that monoallelic MUTYH GPVs are related to renal neoplasia 25 .…”

Section: Discussionmentioning

confidence: 99%

Los olvidados: Non-BRCA variants associated with Hereditary breast cancer in Mexican population

Aguilar,

Garza-Rodríguez,

Muñiz-Garza

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Hereditary predisposition to breast and ovarian cancer syndrome (HBOC) is a pathological condition with increased cancer risk, including breast (BC), ovarian cancer (OC), and others. HBOC pathogenesis is caused mainly by germline pathogenic variants (GPV) in BRCA1 and BRCA2 genes. However, other relevant genes are related to this syndrome diagnosis, prognosis, and treatment, including TP53, PALB2, CHEK2, ATM, etc. This study aimed to identify the prevalence of non-BRCA genes in HBOC patients of Northeast Mexico. Methods: This multicentric study included 1285 patients with HBOC diagnosis from four oncologic centers in northeast Mexico from 2016 to 2023. Genomic and clinical data were analyzed based on multi-gene panel results and electronic records of the medical geneticist consultation. For the data analysis of qualitative and quantitative variants JASP statistical software (version 0.18.1) was used, taking p<0.05 as a significant results. Results: We found that 32.7% of the patients had at least one GPV in non-BRCA genes. The five most frequent non-BRCA genes were CHEK2, PALB2, MUTYH, CDKN2A, and ATM. Among the group of non-BRCA genes, six are involved in the homologous repair pathway (HR), and three are related to DNA damage repair (DDR) pathways. In the analysis of GPVs in molecular pathways, DDR GPVs had a higher risk of developing BC and having cancer between 41-50 years. Conclusion: Multi-gene testing implementation improves the detection of often overlooked genes related to HBOC pathogenesis and treatment. Non-BRCA GPVs in Northern Mexico correspond to one-third of the HBOC cases, including HR and DDR pathways genes that would be misdiagnosed if not tested. HR patient carriers are potential targets of iPARP therapies. The optimal approach to cancer treatment for non-BRCA mutation carriers warrants further investigation to develop newer therapies.

show abstract

Section: Discussionmentioning

confidence: 99%